[go: up one dir, main page]

WO2003037268A3 - Hepta-, octa- and nonapeptides having antiangiogenic activity - Google Patents

Hepta-, octa- and nonapeptides having antiangiogenic activity Download PDF

Info

Publication number
WO2003037268A3
WO2003037268A3 PCT/US2002/034811 US0234811W WO03037268A3 WO 2003037268 A3 WO2003037268 A3 WO 2003037268A3 US 0234811 W US0234811 W US 0234811W WO 03037268 A3 WO03037268 A3 WO 03037268A3
Authority
WO
WIPO (PCT)
Prior art keywords
nonapeptides
hepta
octa
antiangiogenic activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/034811
Other languages
French (fr)
Other versions
WO2003037268A2 (en
Inventor
Fortuna Haviv
Michael F Bradley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,681 external-priority patent/US20030125259A1/en
Priority to NZ532367A priority Critical patent/NZ532367A/en
Priority to KR10-2004-7006643A priority patent/KR20040054759A/en
Priority to EP02789330A priority patent/EP1451210A4/en
Priority to CA2466170A priority patent/CA2466170C/en
Priority to BR0209758-3A priority patent/BR0209758A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to JP2003539614A priority patent/JP4362064B2/en
Priority to IL16152702A priority patent/IL161527A0/en
Priority to MXPA04004131A priority patent/MXPA04004131A/en
Publication of WO2003037268A2 publication Critical patent/WO2003037268A2/en
Publication of WO2003037268A3 publication Critical patent/WO2003037268A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
PCT/US2002/034811 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity Ceased WO2003037268A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA04004131A MXPA04004131A (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity.
KR10-2004-7006643A KR20040054759A (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity
EP02789330A EP1451210A4 (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity
CA2466170A CA2466170C (en) 2001-10-31 2002-10-30 Hexa-, hepta-, and octapeptides having antiangiogenic activity
BR0209758-3A BR0209758A (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having anti-angiogenic activity
NZ532367A NZ532367A (en) 2001-10-31 2002-10-30 HEPTA-, OCTA- and nonapeptides having antiangiogenic activity
JP2003539614A JP4362064B2 (en) 2001-10-31 2002-10-30 Hepta, octa- and nonapeptides with anti-angiogenic activity
IL16152702A IL161527A0 (en) 2001-10-31 2002-10-30 Hepta-, octa-and nonapeptides having antiangiogenic activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/000,681 2001-10-31
US10/000,681 US20030125259A1 (en) 2001-10-31 2001-10-31 Octa- and nonapeptides having antiangiogenic activity
US10/263,812 2002-10-04
US10/263,812 US20030096758A1 (en) 2001-10-31 2002-10-04 HEPTA-, OCTA- and nonapeptides having antiangiogenic activity

Publications (2)

Publication Number Publication Date
WO2003037268A2 WO2003037268A2 (en) 2003-05-08
WO2003037268A3 true WO2003037268A3 (en) 2003-09-12

Family

ID=26667985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034811 Ceased WO2003037268A2 (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity

Country Status (11)

Country Link
EP (1) EP1451210A4 (en)
JP (1) JP4362064B2 (en)
CN (1) CN1639188A (en)
BR (1) BR0209758A (en)
CA (1) CA2466170C (en)
IL (1) IL161527A0 (en)
MX (1) MXPA04004131A (en)
NZ (1) NZ532367A (en)
PL (1) PL374238A1 (en)
TW (1) TWI268934B (en)
WO (1) WO2003037268A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061476A1 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Peptide antiangiogenic drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
JP2002513804A (en) * 1998-05-05 2002-05-14 アドヘレックス テクノロジーズ インコーポレイテッド Compounds and methods for modulating non-classical cadherin-mediated functions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061476A1 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Peptide antiangiogenic drugs

Also Published As

Publication number Publication date
TW200302832A (en) 2003-08-16
CN1639188A (en) 2005-07-13
EP1451210A2 (en) 2004-09-01
JP2005512981A (en) 2005-05-12
IL161527A0 (en) 2004-09-27
CA2466170A1 (en) 2003-05-08
PL374238A1 (en) 2005-10-03
CA2466170C (en) 2011-04-05
TWI268934B (en) 2006-12-21
MXPA04004131A (en) 2004-07-08
EP1451210A4 (en) 2009-05-27
JP4362064B2 (en) 2009-11-11
WO2003037268A2 (en) 2003-05-08
NZ532367A (en) 2006-01-27
BR0209758A (en) 2005-10-04

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2367017A1 (en) Inhibitors of impdh enzyme
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
PL344861A1 (en) Trazinic angiogenesis inhibitiors
MXPA04012965A (en) Viral inhibitors.
WO2002048147A3 (en) Pyrazolopyridines
WO1999054326A8 (en) Dihydropyrimidines
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
MXPA05006196A (en) Compounds and methods for the treatment or prevention of flavivirus.
DE60112330D1 (en) Pyrazolopyridinderivate
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
GB0011203D0 (en) Chemical compounds
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
WO2003037912A3 (en) Tri-, tetra-, and penta-peptides having antiangiogenic activity
WO2001021164A3 (en) Anti-mycobacterium compositions and methods of preparing and using same
GB0102672D0 (en) Compounds
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
WO2003070204A3 (en) Lipase inhibiting composition
AU1041497A (en) Epoxysuccinamide derivative or salt thereof and medicine comprising the same
MXPA04000805A (en) Peptides having antiangiogenic activity.
WO2002026726A3 (en) Antiviral compositions and methods of use
WO2004054513A3 (en) Methods and compositions for treating and preventing ear infections
WO2004073375A3 (en) Podophyllotoxin derivatives as antitumor agents
WO2003037268A3 (en) Hepta-, octa- and nonapeptides having antiangiogenic activity
WO2003065974A3 (en) Hexa-, hepta-, and octapeptides having antiangiogenic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 532367

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 161527

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 374238

Country of ref document: PL

Ref document number: 2002353929

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003539614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/03242

Country of ref document: ZA

Ref document number: 255/MUMNP/2004

Country of ref document: IN

Ref document number: 200403242

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004131

Country of ref document: MX

Ref document number: 2466170

Country of ref document: CA

Ref document number: 1020047006643

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002789330

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 20028258991

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002789330

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0209758

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 532367

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 532367

Country of ref document: NZ